Literature DB >> 17434716

Chronic amphetamine treatment reduces NGF and BDNF in the rat brain.

Francesco Angelucci1, Susanne H M Gruber, Aram El Khoury, Pietro Attilio Tonali, Aleksander A Mathé.   

Abstract

Amphetamines (methamphetamine and d-amphetamine) are dopaminergic and noradrenergic agonists and are highly addictive drugs with neurotoxic effect on the brain. In human subjects, it has also been observed that amphetamine causes psychosis resembling positive symptoms of schizophrenia. Neurotrophins are molecules involved in neuronal survival and plasticity and protect neurons against (BDNF) are the most abundant neurotrophins in the central nervous system (CNS) and are important survival factors for cholinergic and dopaminergic neurons. Interestingly, it has been proposed that deficits in the production or utilization of neurotrophins participate in the pathogenesis of schizophrenia. In this study in order to investigate the mechanism of amphetamine-induced neurotoxicity and further elucidate the role of neurotrophins in the pathogenesis of schizophrenia we administered intraperitoneally d-amphetamine for 8 days to rats and measured the levels of neurotrophins NGF and BDNF in selected brain regions by ELISA. Amphetamine reduced NGF levels in the hippocampus, occipital cortex and hypothalamus and of BDNF in the occipital cortex and hypothalamus. Thus the present data indicate that chronic amphetamine can reduce the levels of NGF and BDNF in selected brain regions. This reduction may account for some of the effects of amphetamine in the CNS neurons and provides evidences for the role of neurotrophins in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434716     DOI: 10.1016/j.euroneuro.2007.03.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

Review 1.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Methamphetamine reversed maternal separation-induced decrease in nerve growth factor in the ventral hippocampus.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2014-01-11       Impact factor: 3.584

3.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

Review 4.  Recovering from cocaine: insights from clinical and preclinical investigations.

Authors:  Colleen A Hanlon; Thomas J R Beveridge; Linda J Porrino
Journal:  Neurosci Biobehav Rev       Date:  2013-04-27       Impact factor: 8.989

5.  Chronic ketamine use increases serum levels of brain-derived neurotrophic factor.

Authors:  Valerio Ricci; Giovanni Martinotti; Francesca Gelfo; Federico Tonioni; Carlo Caltagirone; Pietro Bria; Francesco Angelucci
Journal:  Psychopharmacology (Berl)       Date:  2010-12-14       Impact factor: 4.530

6.  Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Sulail Fatima; Tabassom Beiranvand; Shiva Mozaffari
Journal:  J Neural Transm (Vienna)       Date:  2017-08-09       Impact factor: 3.575

7.  Gestational IV nicotine produces elevated brain-derived neurotrophic factor in the mesocorticolimbic dopamine system of adolescent rat offspring.

Authors:  Steven B Harrod; Ryan T Lacy; Jun Zhu; Benjamin A Hughes; Marla K Perna; Russell W Brown
Journal:  Synapse       Date:  2011-12       Impact factor: 2.562

8.  Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.

Authors:  S Prasad Gabbita; Minu K Srivastava; Pirooz Eslami; Ming F Johnson; Naomi K Kobritz; David Tweedie; Nigel H Greig; Frank P Zemlan; Sherven P Sharma; Marni E Harris-White
Journal:  J Neuroinflammation       Date:  2012-05-25       Impact factor: 8.322

9.  Developing biomarkers for methamphetamine addiction.

Authors:  John Mendelson; Matthew J Baggott; Keith Flower; Gantt Galloway
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

10.  BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation.

Authors:  Elizabeth E Manning; Maarten van den Buuse
Journal:  Front Cell Neurosci       Date:  2013-06-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.